Reglitazar

DB04971ExperimentalSmall molecule

Reglitazar, an isoxazolidine-3,5-dione derivative, is being developed by Pfizer for the treatment of diabetes. It is the first non-thiazolidenedione to enter clinical trials.

Mechanism: Reglixane is an agonist of peroxisome proliferator-activated receptor (PPAR) gamma and alpha.
Curator reviewed
Primary indication: For the treatment of diabetes mellitus type 1 and 2.Curator reviewed
Formula / weight: C₂₂H₂₀N₂O₅ · 392.411 g/mol (avg)
Also known as: Reglixane
Code names: JTT-501 · JTT 501beta · PNU 182716

Resolves to

Compound

UNIIP9UTN18JVVCAS170861-63-9ChEMBLCHEMBL293526PubChem154000

Structure

InChIKeyQBQLYIISSRXYKL-UHFFFAOYSA-NSMILESCC1=C(CCOC2=CC=C(CC3C(=O)NOC3=O)C=C2)N=C(O1)C1=CC=CC=C1

Targets

Q07869PPARAP37231PPARG

What you can answer from here — as of October 01, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Reglitazar, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account